SCHEMBL6794007

SCHEMBL6794007

CC(=O)c1cccc(-c2ccccc2C(=O)Nc2ccnc(CCN(C(=O)O)c3ccccc3)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
ATR Q13535 1/20 0.42
HTT P42858 3/20 0.42
SMO Q99835 1/20 0.41
CHRNB2 P17787 1/20 0.40
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
CHRNA4 P43681 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
LMNA P02545 2/20 0.40
OPRL1 P41146 1/20 0.40
RIPK1 Q13546 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6794001 0.90 SMO (0.47) L3MBTL1ALDH1A1KDM4EGAAATR
SCHEMBL6795031 0.82 SMO (0.40) L3MBTL1ALDH1A1KDM4EGAAHTT
SCHEMBL6795028 0.78 BACE1 (0.41) L3MBTL1ALDH1A1KDM4EGAAHTT
SCHEMBL6644962 0.78 KMT2A (0.42) L3MBTL1ALDH1A1KDM4EGAAHTT
SCHEMBL6642575 0.77 ALDH1A1 (0.49) ALDH1A1KDM4EHTTMEN1KMT2A
SCHEMBL6646976 0.76 MAPT (0.42) L3MBTL1ALDH1A1KDM4EGAAHTT
SCHEMBL7080737 0.76 SMN1; SMN2 (0.50) L3MBTL1ALDH1A1ATRHTTSMO
SCHEMBL6796397 0.75 SMO (0.41) L3MBTL1ALDH1A1KDM4EGAASMO
SCHEMBL6645935 0.72 KMT2A (0.42) L3MBTL1KDM4ELMNAPOLBKMT2A
SCHEMBL6796112 0.72 MEN1 (0.41) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 L3MBTL1 1793/4885ALDH1A1 1427/4885KDM4E 3114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.